Literature DB >> 35023027

Experimental validation of Vitex negundo leaves hydroalcoholic extract for neuroprotection in haloperidol induced parkinson's disease in rat.

Aishwarya Vannur1, Prakash R Biradar2, Vishal Patil3.   

Abstract

Parkinsonism is a neurodegenerative disease, mainly imbalance in dopamine and acetylcholine neurotransimitter in mid brain, which manifestation of dysfunctions of extrapyramidal like akinesia, tremor, rigidity and catalepsy etc., even cognitive and memory loss. The current study is framed to evaluate the effect of Vitex negundo (VNL) leaf extract in Haloperidol induced PD in rats. In vitro studies of antioxidant capacity were checked via DPPH and NO assays and identified its Acetylcholinesterase (AChE) inhibitory activity. Secondly the In vivo study of anti-PD activity in Haloperidol induced in rats were evaluated by Rotarod, morris water maze (MWM), cooks pole climb (CPC), actophotometer, novel object recognition (NOR), and T-maze were utilized to assess extrapyramidal, cognitive and memory function. Thirdly, changes in biomarker level viz. (AChE), butyrylcholinesterase. (BChE) in hippocampus and cortex, reduced glutathione (GSH), malondialdehyde (MDA), total protein (TP), superoxide dismutase (SOD), catalase (CAT), and dopamine level in the whole brain were measured. Finally, histopathology of hippocampus and cortex was examined at 40x magnification to access restoring integrity and maintaining the architecture of neuronal cell in the treatment group compared to control group and L-DOPA as a standard treatment group. V. negundo showed potent antioxidant potency on scavenging of DPPH (IC50 84.81 μg/ml) and NO (IC50 133.20 μg/ml) and possess AChE inhibitory potency (IC50 114.35 μg/ml) by in vitro studies. The Rotarod, MWM, CPC, Actophotometer, NOR, T-maze demonstrated that Haloperidol group administration declines performance time, ELT, TL and decreases locomotion, cognitive and memory respectively. The treatment of VNL 100, 200, and 400 mg/kg p.o. significantly (p < 0.05 to p < 0.0001) reversed. Whole brain AChE, BChE, and MDA level were significantly raised and GSH, TP, SOD, CAT and Dopamine were significantly declined in Haloperidol treated group rats, especially V. negundo 400 mg/kg p.o. highly significantly ameliorate the Haloperidol group altered pathological changes through the restoration of the cholinergic function, enhancing the antioxidant defense and by increasing the dopaminergic function. The current study provides validation of V. negundo for its anti-PD activity and could be a valuable source for the treatment of PD in future.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Haloperidol; L-DOPA; Parkinson’s disease; Vitex negundo L; Vitexine

Mesh:

Substances:

Year:  2022        PMID: 35023027     DOI: 10.1007/s11011-021-00878-2

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  11 in total

Review 1.  Motor control abnormalities in Parkinson's disease.

Authors:  Pietro Mazzoni; Britne Shabbott; Juan Camilo Cortés
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Snake venom neutralization by Indian medicinal plants (Vitex negundo and Emblica officinalis) root extracts.

Authors:  M I Alam; A Gomes
Journal:  J Ethnopharmacol       Date:  2003-05       Impact factor: 4.360

3.  Assessing object-recognition memory in rats: Pitfalls of the existent tasks and the advantages of a new test.

Authors:  Emily Cole; Amanda Simundic; Frank P Mossa; Dave G Mumby
Journal:  Learn Behav       Date:  2019-06       Impact factor: 1.986

Review 4.  Vitex negundo and its medicinal value.

Authors:  Balraj Singh Gill; Richa Mehra; Sanjeev Kumar
Journal:  Mol Biol Rep       Date:  2018-10-11       Impact factor: 2.316

5.  Analysis of behavioral asymmetries in the elevated plus-maze and in the T-maze.

Authors:  Rainer K W Schwarting; Andreas Borta
Journal:  J Neurosci Methods       Date:  2005-02-15       Impact factor: 2.390

Review 6.  Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?

Authors:  O Rascol
Journal:  J Neural Transm Suppl       Date:  1999

Review 7.  Reactive oxygen species: from health to disease.

Authors:  K Brieger; S Schiavone; F J Miller; K-H Krause
Journal:  Swiss Med Wkly       Date:  2012-08-17       Impact factor: 2.193

8.  The Association of Grip Strength With Severity and Duration of Parkinson's: A Cross-Sectional Study.

Authors:  Helen C Roberts; Holly E Syddall; Joe W Butchart; Emma L Stack; Cyrus Cooper; Avan A Sayer
Journal:  Neurorehabil Neural Repair       Date:  2015-02-04       Impact factor: 3.919

9.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

Review 10.  Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.

Authors:  Peng Li; Gretchen L Snyder; Kimberly E Vanover
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

View more
  1 in total

1.  Dose Dependent Effects of Breynia cernua Against the Paraquat Induced Parkinsonism like Symptoms in Animals' Model: In Vitro, In Vivo and Mechanistic Studies.

Authors:  Malik Saadullah; Sania Arif; Liaqat Hussain; Muhammad Asif; Umair Khurshid
Journal:  Dose Response       Date:  2022-09-09       Impact factor: 2.623

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.